Characterization of Progenitor Cells during Canine Retinal Development

Ávila-García, M. C.; García-Sánchez, Gustavo Adolfo; Lira-Romero, Esmeralda; Moreno‐Mendoza, Norma

doi:10.1155/2012/675805

Cited by 6 publications

(6 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HLA-DR expression was very low in both fvERM and primary hRPE cells, while no HLA-G expression was detected on these cells that is in line with previous findings [27–30]. Animal studies have shown that CD117/c-kit is more likely expressed by retinal progenitor cells [31–33] and angiogenic cells [18, 34], which to a certain extent was the case with our primary hRPE, but not the fvERM cells. From the fibroblastoid or mesenchymal stem cell (MSC) markers (CD73, CD90, and CD105) [35], CD73 was present on both fvERM and primary hRPE cells.…”

Section: Discussionsupporting

confidence: 88%

Functional and Molecular Characterization ofEx VivoCultured Epiretinal Membrane Cells from Human Proliferative Diabetic Retinopathy

Veréb

Lumi

Andjelić

et al. 2013

BioMed Research International

View full text Add to dashboard Cite

Characterization of the cell surface marker phenotype of ex vivo cultured cells growing out of human fibrovascular epiretinal membranes (fvERMs) from proliferative diabetic retinopathy (PDR) can give insight into their function in immunity, angiogenesis, and retinal detachment. FvERMs from uneventful vitrectomies due to PDR were cultured adherently ex vivo. Surface marker analysis, release of immunity- and angiogenesis-pathway-related factors upon TNFα activation and measurement of the intracellular calcium dynamics upon mechano-stimulation using fluorescent dye Fura-2 were all performed. FvERMs formed proliferating cell monolayers when cultured ex vivo, which were negative for endothelial cell markers (CD31, VEGFR2), partially positive for hematopoietic- (CD34, CD47) and mesenchymal stem cell markers (CD73, CD90/Thy-1, and PDGFRβ), and negative for CD105. CD146/MCAM and CD166/ALCAM, previously unreported in cells from fvERMs, were also expressed. Secretion of 11 angiogenesis-related factors (DPPIV/CD26, EG-VEGF/PK1, ET-1, IGFBP-2 and 3, IL-8/CXCL8, MCP-1/CCL2, MMP-9, PTX3/TSG-14, Serpin E1/PAI-1, Serpin F1/PEDF, TIMP-1, and TSP-1) were detected upon TNFα activation of fvERM cells. Mechano-stimulation of these cells induced intracellular calcium propagation representing functional viability and role of these cells in tractional retinal detachment, thus serving as a model for studying tractional forces present in fvERMs in PDR ex vivo.

show abstract

Section: Discussionsupporting

confidence: 88%

Functional and Molecular Characterization ofEx VivoCultured Epiretinal Membrane Cells from Human Proliferative Diabetic Retinopathy

Veréb

Lumi

Andjelić

et al. 2013

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…1-3) and BDNF (Figs. [4][5][6] immunolabeling patterns were similar, with labeling being either locally extensive or diffuse. The intensity of immunolabeling varied from weak to strong within the same tumor.…”

Section: Prongf and Bdnf Expressionmentioning

confidence: 85%

Expression and Prognostic Significance of Neurotrophins and Their Receptors in Canine Mammary Tumors

et al. 2020

View full text Add to dashboard Cite

Accumulating data highlight the role of neurotrophins and their receptors in human breast cancer. This family includes nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF), both synthetized as proneurotrophins (proNGF and proBDNF). (pro)NGF and (pro)BDNF initiate their biological effects by binding to both their specific receptors TrkA and TrkB, respectively, and the common receptor p75NTR. Currently, no data are available about their expression and potential role in canine mammary tumors. The aim of this study was to investigate expression of proNGF and BDNF as well as their receptors TrkA, TrkB, and p75NTR in canine mammary carcinomas, and to correlate them with clinicopathological parameters (grade, histological type, lymph node status, recurrence, and distant metastasis) and survival. Immunohistochemistry was performed on serial sections of 96 canine mammary carcinomas with antibodies against proNGF, BDNF, TrkA, TrkB, and p75NTR. Of the 96 carcinomas, proNGF expression was detected in 71 (74%), BDNF in 79 (82%), TrkA in 94 (98%), TrkB in 35 (37%), and p75NTR in 44 (46%). No association was observed between proNGF, BDNF, or TrkA expression and either clinicopathological parameters or survival. TrkB and p75NTR expression were associated with favorable clinicopathological parameters as well as better overall survival.

show abstract

“…The tyrosine kinase receptor c-kit is activated by its ligand stem cell factor and acts as the primary growth factor for mast cells. It is also expressed in a range of other cell types including melanocytes, mammary cells, Purkinje cells, interstitial cells of Cajal, neuroblastic cells of the retina, Leydig cells and spermatogonia, mature dendritic cells and most (but not all) haematopoietic stem cells (Rico-Vargas et al 1994, Huss et al 1995, Reguera et al 2000, Morini et al 2004, Gilfillan & Rivera 2009, Usher et al 2009, Grieco et al 2010, Avila-Garcia et al 2012, Lennartsson & Ronnstrand 2012.…”

Section: Choosing Medical Therapy For Mct Based On the Presence Of C-kit Mutationmentioning

confidence: 99%

Molecular pathology in the cancer clinic – where are we now and where are we headed?

Guillén

Smallwood

Killick

2021

J of Small Animal Practice

View full text Add to dashboard Cite

Molecular pathology is a developing sub-microscopic discipline of pathology that studies the effects of molecular variations and mutations on disease processes. The ultimate goal of molecular pathology in cancer is to predict risk, facilitate diagnosis and improve prognostication based on a complete understanding of the biological impact of specific molecular variations, mutations and dysregulations. This knowledge will provide the basis for customised cancer treatment, so-called precision medicine. Rapid developments in genomics have placed this field at the forefront of clinical molecular pathology and there are already a number of well-established genetic tests available for clinical use including PCR of antigen receptor rearrangement and KIT mutational analysis. Moving beyond tests assessing a single gene, there are significant research efforts utilising genomics to predict cancer risk, forecast aggressive behaviour and identify druggable mutations and therapeutic biomarkers. Researchers are also investigating the use of circulating cells and nucleic acid for clinically useful low morbidity genomic assessments. If we are to realise the full potential of molecular pathology and precision medicine there are a number of challenges to overcome. These include developing our understanding of the underlying biology (in particular intra-tumoural heterogeneity), methodological standardisation of assays, provision of adequate infrastructure and production of novel therapeutics backed by high-quality clinical data supporting the precision medicine approach. The era of molecular pathology holds the potential to revolutionise veterinary cancer care, but its impact on clinical practice will depend upon the extent to which the inherent challenges can be overcome.

show abstract

Characterization of Progenitor Cells during Canine Retinal Development

Cited by 6 publications

References 47 publications

Functional and Molecular Characterization ofEx VivoCultured Epiretinal Membrane Cells from Human Proliferative Diabetic Retinopathy

Functional and Molecular Characterization ofEx VivoCultured Epiretinal Membrane Cells from Human Proliferative Diabetic Retinopathy

Expression and Prognostic Significance of Neurotrophins and Their Receptors in Canine Mammary Tumors

Molecular pathology in the cancer clinic – where are we now and where are we headed?

Contact Info

Product

Resources

About